Evommune, Inc. (EVMN)

Evommune Balance Sheet

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	FY 2025	FY 2024	FY 2023
Period Ending	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023
Cash & Equivalents	44.06	16.26	29.02
Short-Term Investments	105.14	55.79	50.06
Cash & Short-Term Investments	149.2	72.04	79.08
Cash Growth	107.11%	-8.91%	-
Prepaid Expenses	4.28	1.95	0.95
Total Current Assets	153.48	73.99	80.03
Property, Plant & Equipment	2.46	1.8	1.97
Long-Term Investments	67.49	-	-
Other Long-Term Assets	1.52	0.27	0.25
Total Assets	224.95	76.06	82.25
Accounts Payable	7.76	8.26	1.76
Accrued Expenses	9.55	6.73	4.03
Current Portion of Leases	0.59	0.49	0.77
Current Unearned Revenue	-	3	-
Other Current Liabilities	0.02	9.5	0.3
Total Current Liabilities	17.91	27.98	6.86
Long-Term Leases	1.47	-	0.49
Long-Term Deferred Tax Liabilities	-	-	3
Other Long-Term Liabilities	-	0.54	0.25
Total Liabilities	19.38	28.52	10.59
Common Stock	0	-	0
Additional Paid-In Capital	426.65	7.98	6.2
Retained Earnings	-221.09	-152.22	-83.91
Total Common Equity	205.57	-144.24	-77.71
Shareholders' Equity	205.57	47.54	71.66
Total Liabilities & Equity	224.95	76.06	82.25
Total Debt	2.06	0.49	1.26
Net Cash (Debt)	147.14	71.55	77.83
Net Cash Growth	105.64%	-8.06%	-
Net Cash Per Share	23.98	47.44	62.10
Filing Date Shares Outstanding	36.02	1.55	1.25
Total Common Shares Outstanding	31.52	1.55	1.25
Working Capital	135.57	46.01	73.18
Book Value Per Share	6.52	-92.97	-62.01
Tangible Book Value	205.57	-144.24	-77.71
Tangible Book Value Per Share	6.52	-92.97	-62.01
Machinery	0.83	0.67	-
Construction In Progress	0.04	-	-
Leasehold Improvements	0.53	0.46	-

Source: S&P Global Market Intelligence. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q